Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linzagolix

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            Trial assessed safety and tolerability of daily oral linzagolix doses in women with endometriosis-associated pain. linzagolix significantly improved in quality of life after 52 weeks of treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nolasiban

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Yuyuan BioScience Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            This sublicense agreement aims to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).